One-year follow-up study of patients with enterochromaffin-like cell carcinoids after treatment with octreotide long-acting release

Abstract

During follow-up, slightly elevated levels of serum CgA and CgA IR cells in the oxyntic mucosa, without significant recurrence of ECL cell carcinoids, were observed.

Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs

“…The pathological examinations showed that, after 6 months, there was a regression from endocrine tumor to micronodular hyperplasia in eight patients (88.9%), while, after 12 months, the neoplasia disappeared in all the patients examined. These data are similar to those previously found by Fykse et al (2004Fykse et al ( , 2005 www.endocrinology-journals.org the author had treated five patients with one to five gastric endocrine tumors in CAG with octreotide-LAR 20 mg for 12 months. Moreover, we obtained the complete regression of endocrine tumors to simple hyperplasia in patients with higher number of lesions using octreotide-LAR 30 mg.…”

“…Further studies on a more consistent number of patients are necessary to confirm this initial observation and, most of all, to describe what happens in the long term after the end of treatment. In fact some authors reported a rebound of gastric endocrine cell after drug withdrawal without recurrence of gastric endocrine tumors (Bordi et al 1993, Fykse et al 2005.…”

Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A

“…Octreotide is a somatostatin analogue and has been used to treat patients with type I GC with regression of carcinoids after 1-year treatment. [13][14][15] The long-term efficacy of somatostatin analogue treatment is unknown, but 5 years after stopping octreotide, many patients had progression of carcinoids, 16 suggesting a possible rebound effect after stopping treatment. Type 1 GC may be removed endoscopically, but recurrence occurs in the majority of patients.…”

Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids

“…In a previous study, we showed that octreotide long-acting release (LAR) given as monthly injections for 1 year had an anti-proliferative effect on ECL cells and tumor cells in GC1 patients and may be an alternative treatment for patients with GC1 [25,26,28]. The follow-up study showed that the treatment effect persisted 1 year [29] or even up to 3 years after treatment discontinuation [30]. However, the optimal duration of octreotide treatment is unknown.…”